Drug Profile
Research programme: botulinum toxin-based therapeutics - AbbVie/Meditox
Alternative Names: botulinum toxin; botulinum toxin B - MedytoxLatest Information Update: 15 Dec 2021
Price :
$50
*
At a glance
- Originator Medy-Tox
- Class Bacterial proteins; Bacterial toxins
- Mechanism of Action Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spasm
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Nov 2017 No recent reports of development identified for preclinical development in Spasm in South Korea (Parenteral, Injection)
- 25 Sep 2013 Neurotoxin-based therapeutics licensed to Allergan worldwide (excluding Korea)